Page 213 - Drug Class Review
P. 213
Drug Effectiveness Review Project
Drugs Authors: Tariot et al. 47 Eisai, Inc; Pfizer, Inc To evaluate the safety and efficacy of DON in the management of patients with AD residing in nursing Setting: Multi-center (27) placebo donepezil N/A 5 mg/d; 10 mg/d 24 weeks 4 weeks; 20 weeks 105 103 Diagnosis of possible or probable AD with CVD according to NINCDS/ADRDA; MMSE score between 5 and 26 inclusive; reported frequency of a symptom at least several times a week from NPI-NH; sufficient vision and hearing; resided in nursing home for at least 1 month before study Parkinson’s, VaD or other neurological dise
Alzheimer Year: 2001 Country: US home facilities Study design: RCT Sample size: 208
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
